Switching to a two-drug HIV pill vs. staying on three drugs
Part of Immune system & allergy, Infections clinical trials.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your HIV has been undetectable (suppressed) for at least 48 weeks.
- You are currently taking Biktarvy or Triumeq.
- You have never had a viral load increase while on treatment (virologic failure).
- Your kidney function is good (eGFR 60 or higher).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether people with both HIV and hepatitis B (HBV) can safely stop or switch parts of their antiviral treatment. It aims to see if simpler treatment can keep both viruses under control for 96 weeks.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This trial tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in men whose HIV is already suppressed. The goal is to find a simpler, effective option that may have fewer side effects.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.